A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2004
10/21/2004	US20040209804 comprises calcium for stable, extendend release; improved bioavailability; protamines; for treatment of turner's syndrome, crohn's disease, burns
10/21/2004	US20040209803 comprises incretin, glucagon-like peptide-1, an exendin, and agonist;; insulin resistance; reducing proteinuria
10/21/2004	US20040209802 Administering erythropoietin or derivative to treat diabetes
10/21/2004	US20040209801 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits
10/21/2004	US20040209800 Use of mx gtpases in the prognosis and treatment of cancer
10/21/2004	US20040209799 comprises inhibitors (cytokines) of janus kinases (JAK)/signal transducers and activators of transcription (STAT) other than debromohymenialdisine and hymensialdisine; gene expression inhibition; bioassay, immunoassay, drug screening; for treatment of degenerative joint diseases such as osteoarthritis
10/21/2004	US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites
10/21/2004	US20040209797 comprises protein transduction domains; nuclear localization sequences; fusion proteins; for reversible immortalization of cells
10/21/2004	US20040209379 Diagnosis and monitoring of diseases
10/21/2004	US20040209358 Oligonucleotide sequences for use in controlling gene expression of serum response factor accessory protein-1 (SAP-I) gene for use in treatment of cell proliferative disorders; gene therapy and antiproliferfative agents; gene expression inhibition
10/21/2004	US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases
10/21/2004	US20040209328 Human tumor necrosis factor receptor TR16
10/21/2004	US20040209327 Regulation of human transmembrane serine protease
10/21/2004	US20040209326 Immunoglobulin for use in detection and prevention staphylococcus infections
10/21/2004	US20040209324 Comprises genetically altered thrombopoietin for use in treatment of thrombocytopenia; gene therapy and therapeutic proteins
10/21/2004	US20040209314 Comprises multimer of major histocompatibility complex which binds peptide-specific CD8+ T lymphocyte populations for use as diagnostic components of immunoassay; immunotherapy
10/21/2004	US20040209310 Ligands that bind to the amyloid-beta precursor peptide and related molecules and uses thereof
10/21/2004	US20040209306 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
10/21/2004	US20040209292 Mutant human hepatitis B viral strain and uses thereof
10/21/2004	US20040209287 OCT1p, a protein having homology to the organic and sugar transporter family of proteins, and uses thereof
10/21/2004	US20040209265 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins and uses thereof
10/21/2004	US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders
10/21/2004	US20040209263 Selection of catalytic nucleic acids targeted to infectious agents
10/21/2004	US20040208935 Small particle liposome aerosols for delivery of anti-cancer drugs
10/21/2004	US20040208934 Dispersions or complexes of calcium phosphate in polymers such as polyethylene glycol or dextran sulfate; solid matrix due to hydration; contains active agent; matrix polymer and/or complexing agent slows release of active agent from solid matrix
10/21/2004	US20040208929 specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition
10/21/2004	US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability
10/21/2004	US20040208920 injectable liposomal composition for delivery of large amounts of water-soluble substance comprises a plurality of liposomal vesicles having a high weight ratio of lipid to encapsulated water-soluble substance which is distributed over the liposomal vesicles; high efficiency of encapsulation
10/21/2004	US20040208899 Apparatus for diagnosis and treatment of swine infertility and respiratory virus (SIRS) syndrome; vaccines
10/21/2004	US20040208890 secreted Chlamydia polypeptides expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway; vaccination, and diagnostic uses
10/21/2004	US20040208889 Pharmaceutical use for secreted bacterial effector proteins
10/21/2004	US20040208888 Method of and compositions for immunization with the pseudomonas v antigen
10/21/2004	US20040208886 DNA sequences encoding the proteins; drugs with the proteins or the DNA; for the preparation of antigens for treating tumoral diseases; administering
10/21/2004	US20040208885 Immunoregulatoratory compositions
10/21/2004	US20040208884 Administering construct in conjugated or unconjugated form and in combination with immunogenic carrier to induce antibodies; anticarcinogenic agents
10/21/2004	US20040208881 B1k chain of laminin and methods of use
10/21/2004	US20040208880 Targeting cellular entry, cell survival, and pathogenicity by dynein light chain 1/PIN in human cells
10/21/2004	US20040208879 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
10/21/2004	US20040208878 Treatment of acute lung injury, fibrosis and metastasis with antagonists of alphabetav6
10/21/2004	US20040208874 Treating a tumor necrosis factor (TNF)- alpha mediated disease by administering TNF- alpha inhibitor and a B7gene or protein inhibitor and/or a CD28/antigen/ inhibitor; antiinflammatory agents; arthritis, autoimmune diseases, inflammatory bowel disease, psoriasis, lupus, graft versus host disease
10/21/2004	US20040208871 Pharmaceutical composition containing inhibitors of interferon-gamma
10/21/2004	US20040208867 Mutant protein with amino acid sequence that is substituted, deleted, inserted or transposed; 3'-phosphoadenosine5'-phosphosulfate; gene expression; medical diagnosis
10/21/2004	US20040208866 Methods of regulating body weight
10/21/2004	US20040208863 Anti-inflammatory activity from lactic acid bacteria
10/21/2004	US20040208862 Neuronal regeneration
10/21/2004	US20040208856 Oligonucleotides targeted to nucleic acid encoding apolipoprotein C-III; gene expression inhibition; medical diagnosis
10/21/2004	US20040208851 Immunization by inoculation of DNA transcription unit
10/21/2004	US20040208846 Mini-Ad vector for immunization
10/21/2004	US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents
10/21/2004	US20040208829 Methods and compositions for treating erectile dysfunction
10/21/2004	US20040208786 Autologous coagulant produced from anticoagulated whole blood
10/21/2004	US20040208308 Personal communication center performance display and status alert system
10/21/2004	DE202004012807U1 Kosmetische und dermatologische Zusammensetzungen mit DNA-Reparaturenzymen und Oligopeptiden Cosmetic and dermatological compositions with DNA repair enzymes and oligopeptides
10/21/2004	CA2843439A1 Reversible pegylated drugs
10/21/2004	CA2809195A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
10/21/2004	CA2784829A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
10/21/2004	CA2563393A1 Ml - iap peptides induce anti-melanoma cytotoxic t-cell response
10/21/2004	CA2524246A1 Process for producing albumin preparations comprising virus-removing filtration
10/21/2004	CA2522456A1 Nucleotide and cellular vaccine composition
10/21/2004	CA2521931A1 Use of hcv proteins
10/21/2004	CA2521855A1 Feminine hygiene composition comprising an equid milk extract
10/21/2004	CA2521713A1 Anti-fungal peptidomimetics
10/21/2004	CA2521631A1 Composition with heart rate reducing properties
10/21/2004	CA2521602A1 Therapeutic composition for autoimmune conditions
10/21/2004	CA2521469A1 Identification of novel nogo-receptors and methods related thereto
10/21/2004	CA2521402A1 Pectate lyases, nucleic acids encoding them and methods for making and using them
10/21/2004	CA2521273A1 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
10/21/2004	CA2521217A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
10/21/2004	CA2520865A1 Zwitterionic immunomodulators for the treatment of asthma and allergy
10/21/2004	CA2520775A1 Non-aqueous single phase vehicles and formulations utilizing such vehicles
10/21/2004	CA2520763A1 Improved inhibitors for the soluble epoxide hydrolase
10/21/2004	CA2520023A1 Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
10/21/2004	CA2519975A1 Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
10/21/2004	CA2519927A1 Novel probiotic compositions and methods of using the same
10/20/2004	EP1469310A1 Diagnostic for scleroderma
10/20/2004	EP1469077A1 Cell-specific expression/replication vector
10/20/2004	EP1469075A1 Gene-therapy for solid tumors, papillomas and warts
10/20/2004	EP1469074A1 Human calcium channel compositions and methods
10/20/2004	EP1469073A2 Polynucleotides and membrane-bound polypeptides encoded thereby
10/20/2004	EP1469070A1 Livin-specific siRNAs for the treatment of therapy-resistant tumors
10/20/2004	EP1469011A1 Hemoglobin conjugates
10/20/2004	EP1469009A2 Compositions and methods for non-parenteral delivery of oligonucleotides
10/20/2004	EP1468695A1 Methods and compositions useful for inhibition of angiogenesis
10/20/2004	EP1468694A1 Remedies for anorexia or lifestyle-related diseases and method of screening the same
10/20/2004	EP1468690A1 Use of estrogens for the treatment of infertility in male mammals
10/20/2004	EP1468265A1 Systems and methods for the analysis of protein phosphorylation
10/20/2004	EP1468119A2 A METHOD OF DEVELOPING AN ANTI−PROTEIN AND REGULATION OF A CELLULAR FUNCTION BY ADMINISTERING AN EFFECTIVE AMOUNT OF THE ANTI−PROTEIN
10/20/2004	EP1468098A2 Method of inhibiting pathogenicity of infectious agents
10/20/2004	EP1468097A2 METHODS OF GENERATING MULTISPECIFIC, MULTIVALENT AGENTS FROM V sb H /sb AND V sb L /sb DOMAINS
10/20/2004	EP1468092A2 Pim-3 kinase as a target for type 2 diabetes mellitus
10/20/2004	EP1468091A2 Transmembrane protein
10/20/2004	EP1468085A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
10/20/2004	EP1468076A1 Defective entities and uses therefor
10/20/2004	EP1468021A2 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
10/20/2004	EP1468020A2 Multimers of receptor-binding ligands
10/20/2004	EP1468019A2 Secreted protein
10/20/2004	EP1468018A2 Leptin proteins
10/20/2004	EP1468017A1 A complex of a human foxc2 protein and a foxc2-interacting protein
10/20/2004	EP1468016A2 Genetic polymorphisms predicting cardiovascular disease and medication efficacy
10/20/2004	EP1468014A2 Compositions and methods for wt1 specific immunotherapy

1 ... 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 ... 3163